Functional GI Disorders Common in MS

Key clinical point: Managing comorbid psychiatric disorders in patients with MS could reduce the burden of functional GI disorders.

Major finding: Approximately 42% of patients with MS report functional GI disorders.

Study details: A survey of 6,312 participants in the North American Research Committee on MS Registry.

Disclosures: The study had no sponsor. Dr. Marrie had no disclosures, but other researchers had financial relationships with pharmaceutical companies, such as Merck, Novartis, Roche, Sanofi-Aventis, and Teva.

Citation: Marrie RA et al. CMSC 2019, Abstract QOL13.

Key clinical point: Managing comorbid psychiatric disorders in patients with MS could reduce the burden of functional GI disorders.

Major finding: Approximately 42% of patients with MS report functional GI disorders.

Study details: A survey of 6,312 participants in the North American Research Committee on MS Registry.

Disclosures: The study had no sponsor. Dr. Marrie had no disclosures, but other researchers had financial relationships with pharmaceutical companies, such as Merck, Novartis, Roche, Sanofi-Aventis, and Teva.

Citation: Marrie RA et al. CMSC 2019, Abstract QOL13.

Key clinical point: Managing comorbid psychiatric disorders in patients with MS could reduce the burden of functional GI disorders.

Major finding: Approximately 42% of patients with MS report functional GI disorders.

Study details: A survey of 6,312 participants in the North American Research Committee on MS Registry.

Disclosures: The study had no sponsor. Dr. Marrie had no disclosures, but other researchers had financial relationships with pharmaceutical companies, such as Merck, Novartis, Roche, Sanofi-Aventis, and Teva.

Citation: Marrie RA et al. CMSC 2019, Abstract QOL13.